New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 23, 2013
15:03 EDTALXNAlexion down 4.7% after UK ministers say will not follow Soliris recommendation
News For ALXN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 27, 2014
08:15 EDTALXNAlexion says NICE recommends Soliris for aHUS patients
Subscribe for More Information
November 25, 2014
06:35 EDTALXNAlexion's Soliris granted ODD in Japan
Alexion Pharmaceuticals announced that Soliris, or eculizumab, has been granted orphan drug designation, or ODD, by Japanís Ministry of Health, Labour and Welfare for the treatment of patients with neuromyelitis optica, or NMO, a life-threatening, ultra-rare neurologic disorder. In patients with NMO, chronic, uncontrolled complement activation results in severe damage to the central nervous system, predominantly impacting the optic nerve and spinal cord.1-3 This devastating disease is characterized by severe weakness, paralysis, respiratory failure, loss of bowel and bladder function, blindness and premature death.4-6
November 20, 2014
07:09 EDTALXNAlexion management to meet with Deutsche Bank
Subscribe for More Information
November 19, 2014
10:28 EDTALXNAlexion management to meet with Deutsche Bank
Subscribe for More Information
November 18, 2014
07:52 EDTALXNFDA Drug Safety & Risk Management Advisory Committee to hold a meeting
The Committee discusses the risk management of Alexion Pharmaceuticals' Eculizumab (Soliris) is a meeting being held at FDA Silver Spring, Maryland offices on November 18 at 9 am. Webcast Link
November 16, 2014
13:04 EDTALXNAlexion says data supports effectiveness of sustained Soliris treatment in aHUS
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use